This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Q.-S. Articles by Grompe, M. Search for Related Content PubMed PubMed Citation Articles by Zhang, Q.-S. Articles by Grompe, M. Related Collections Preclinical Intervention Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms

Tempol Protects against Oxidative Damage and Delays Epithelial Tumor Onset in Fanconi Anemia Mice

¹ Oregon Stem Cell Center, Oregon Health and Science University, Portland, Oregon; ² Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders and ³ Radiation Biology Branch, National Cancer Institute, NIH, Bethesda, Maryland; and ⁴ Department of Pathology, Texas Children's Hospital, Houston, Texas

Requests for reprints: Qing-Shuo Zhang, Oregon Stem Cell Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239. Phone: 503-494-6889; Fax: 503-494-5044; E-mail: zhangqi{at}ohsu.edu.

Key Words: Fanconi anemia • tempol • antioxidant • cancer • oxidative stress

Fanconi anemia (FA) is a genetic disorder characterized by congenital abnormalities, bone marrow failure, and marked cancer susceptibility. FA patients have an elevated risk of developing hematologic malignancies and solid tumors. Using Fancd2^–/– knockout mice as a model of FA, we examined the potential of tempol, a nitroxide antioxidant and a superoxide dismutase mimetic, as a tumor-delaying agent for solid tumors. Dietary tempol increased the mean tumor-free survival time of Fancd2^–/– Trp53^+/– mice by 27% (P < 0.01), from 308 to 390 days, without changing the overall tumor spectrum. More strikingly, tempol delayed the onset of epithelial tumors and increased the mean epithelial tumor-free survival time by 38% (P < 0.0001), from 312 to 432 days, in Fancd2^–/– Trp53^+/– mice. These results show that tempol can significantly delay tumor formation in Fancd2^–/– Trp53^+/– mice. Furthermore, tempol treatment did not adversely affect the repopulating ability of FA hematopoietic stem cells. The reduction in oxidative DNA damage in tempol-treated FA fibroblasts and mice suggests that its tumor-delaying function may be attributed to its antioxidant activity. [Cancer Res 2008;68(5):1601–8]

This article has been cited by other articles:

				M. C. Ghosh, W.-H. Tong, D. Zhang, H. Ollivierre-Wilson, A. Singh, M. C. Krishna, J. B. Mitchell, and T. A. Rouault Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice PNAS, August 19, 2008; 105(33): 12028 - 12033. [Abstract] [Full Text] [PDF]